A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT PEMBROLIZUMAB IN THE TREATMENT OF PATIENTS WITH EARLY-STAGE (STAGES IB-III) NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING COMPLETE RESECTION AND PLATINUM-BASED CHEMOTHERAPY

被引：0
|
作者：
Draganigos, A. [1 ]
Nguyen, S. [1 ]
Skroumpelos, A. [2 ]
Iliopoulou, E. [2 ]
Mylonas, C. [2 ]
Karokis, A. [2 ]
机构：
[1] MSD Greece, Athens A1, Greece
[2] MSD Greece, Alimos, Attica, Greece
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE192
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [41] Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
    Wood, Cameron
    Lyniv, Liliana
    Isaacs, James M.
    Kaufman, Jacob M.
    Oduah, Eziafa, I
    Clarke, Jeff
    Crawford, Jeffrey
    Stinchcombe, Thomas
    Tong, Betty C.
    Wang, Xiaofei
    Gu, Lin
    Wigle, Dennis
    Dragnev, Konstantin H.
    Antonia, Scott J.
    Weinhold, Kent
    Ready, Neal
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [42] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
    Ciuleanu, T. E.
    Dediu, M.
    Minea, L. N.
    Baculea, S.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2010, 13 (03) : A38 - A38
  • [43] CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS OF PATIENTS WITH EARLY-STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
    Flores-Caballero, M. A.
    Lugo-Martinez, G.
    Rodriguez-Cid, J. R.
    Juarez-Vignon Whaley, J.
    Cruz-Zermeno, M.
    Seidman-Sorsby, A.
    Martinez-Herrera, F.
    Garcia-Montes, V
    Garibay-Diaz, J. C.
    Espinosa, Gonzalez, I
    Hernandez-Flores, O.
    Oyervides-Juarez, V. M.
    Gonzalez-Cisneros, P.
    Sala, Riera R.
    Alatorre-Alexander, J.
    Betancur, M. A.
    Medina, S.
    Rojowska, A.
    Lopez Lopez, F.
    VALUE IN HEALTH, 2023, 26 (12) : S217 - S217
  • [44] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH PLATINUM CHEMOTHERAPY AND PEMETREXED FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND
    Harding, T.
    Insinga, R.
    Dawson, H.
    Bates, B. E.
    Arunachalam, A.
    Vandormael, K.
    VALUE IN HEALTH, 2019, 22 : S473 - S473
  • [45] Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
    Yin, Ji-Ye
    Huang, Qiong
    Zhao, Ying-Chun
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    PLOS ONE, 2012, 7 (06):
  • [46] Molecular profiles of predictive biomarkers for platinum-based chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
    Seyedabadi, NiloofarTaleghani
    Shoushtari, Sara YousefZadeh
    Soofi, Asma
    Arabpour, Javad
    Shams, Zinat
    Akhavan, Homa
    Hosseini-Asl, Saied
    META GENE, 2022, 31
  • [47] Patient and clinician perspectives on adjuvant treatment in early-stage non-small cell lung cancer (NSCLC): Qualitative results
    Collacott, H.
    Okhuoya, P.
    Sandelin, M.
    Michaels-Igbokwe, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S100 - S100
  • [48] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
    Chouaid, C.
    Bensimon, L.
    Tardu, J.
    Millier, A.
    Insinga, R.
    Rai, A.
    Levy-Bachelot, L.
    Levy, P.
    VALUE IN HEALTH, 2020, 23 : S433 - S433
  • [49] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
    Zeng, Xiaohui
    Wan, Xiaomin
    Peng, Liubao
    Peng, Ye
    Ma, Fang
    Liu, Qiao
    Tan, Chongqing
    BMJ OPEN, 2019, 9 (12): : e031019
  • [50] Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
    Aziz, Mohamed Ismail Abdul
    Tan, Ling Eng
    Tan, Wan Hui Gloria
    Toh, Chee-Keong
    Loke, Lydia Pui Yee
    Pearce, Fiona
    Ng, Kwong
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (09) : 952 - 960
12345